Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2026-04-03 10:45:44 ET · period of report 2026-04-01 · accession 0001470831-26-000345 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 10:45 | 2026-04-01 | CCCC | GROGAN DONNA ROY | Dir | A - Grant | $2.70 | +5,370 | 71.5K | +8% | +$14.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | A | A | 5,370 | $2.70 | 71,512 | D | — | — | (F1) These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. (F2) The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026. |